Sales of Tylenol surged 43% YoY, compared to the same quarter of the previous year in the OTC pain medication market. This is in stark contrast to the double-digit decline in sales of other pain medications.

Analysts believe that this increase in sales was influenced by the government’s guidance to ‘use Tylenol when experiencing side effects after COVID-19 vaccination.’ However, in the prolonged Tylenol shortage, companies with other analgesic brands have been employing aggressive marketing strategies targeting the gap, which may affect their Q2 sales and thereafter.

◆₩10.2 billion → ₩14.7 billion in one year… Tylenol makes new quarterly sales record